RxSight(US:RXST) GlobeNewswire News Room·2025-08-12 16:44Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of misleading statements and failure to disclose significant operational challenges that have negatively impacted the company's financial performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - Investors who suffered losses in RxSight between November 7, 2024, and July 8, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. Group 2: Allegations Against RxSight - The complaint alleges that RxSight and its executives violated federal securities laws by making false or misleading statements regarding the company's sales and product demand [6]. - Specific allegations include that the company faced "adoption challenges" leading to declines in sales and utilization, overstated demand for its products, and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [6]. Group 3: Financial Performance and Market Reaction - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, along with a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following this announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, amid unusually heavy trading volume [7].